




# CXCL8 derived from tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression by promoting migration and invasion of cancer cells


## SUPPLEMENTARY MATERIALS




**Supplementary Figure 1: rhIL-4 up-regulated the expression level of CXCL8 in PBMo-derived macrophages.** The mRNA level of *CXCL8* in PBMo-derived macrophages stimulated with 50% TE-9 CM or rhIL-4 (20 ng/ml) was determined by quantitative RT-PCR. The data were normalized to *GAPDH* as an internal control. Data are mean  $\pm$  SEM in triplicate. \*\*\* $p < 0.001$ .

**A****B**


**Supplementary Figure 2: rhCXCL8 did not induce migration of TE-15.** Neutralizing antibody against CXCL8 tended to suppress migration of TE-15. **(A)** For the transwell migration assay, TE-15 cells were plated on the transwell in serum-free RPMI-1640 at  $1.0 \times 10^6$  cells/well. rhCXCL8 was added in the upper chamber at 100 ng/ml. The cell inserts were set on 24-well plates in RPMI-1640 with 10% FBS for 48 h. The migrated cells on the underside of the membrane were stained by Diff-Quik and counted. **(B)** TE-15 cells were plated on the transwell in serum-free RPMI-1640 at  $1.0 \times 10^6$  cells/well. Neutralizing antibody against CXCL8 was added in the upper chamber at 1.0 µg/ml. The cell inserts were set on 24-well plates in RPMI-1640 with 10% FBS for 48 h. The migrated cells on the underside of the membrane were stained by Diff-Quik and counted. The results are mean  $\pm$  SEM. NS, not significant.



**Supplementary Figure 3: CXCL8 did not promote growth and survival of TE-8 cells.** TE-8 seeded on 96 well plate with serum free medium or medium with 1% serum treated with CXCL8 (0, 1, 10, 100 ng/ml) for 96 h. Cell growth and survival activity were assessed by MTS assay. The results are presented as the mean  $\pm$  SEM. NC, negative control; NS, not significant.





**Supplementary Figure 4: CXCL8 promoted the migration and invasion of TE-9 cells.** (A) (i) For the transwell migration assay, TE-9 cells were plated on the transwell in serum-free RPMI-1640 at  $5.0 \times 10^5$  cells/well. rhCXCL8 was added in the upper chamber at 10 ng/ml. The cell inserts were set on 24-well plates in RPMI-1640 with 1% FBS for 24 h. The migrated cells on the underside of the membrane were stained by Diff-Quik and counted. The results are mean  $\pm$  SEM. (ii) For the transwell invasion assay, TE-9 cells were seeded on a transwell coated with matrigel in serum-free RPMI-1640 at  $5.0 \times 10^5$  cells/well. rhCXCL8 was added in the transwell at 100 ng/ml. The cell inserts were set on 24-well plates in RPMI-1640 with 1% FBS for 48 h. The invaded cells on the underside of the membrane were stained by Diff-Quik and counted. (B) (i) TE-9 cells were plated on the upper chamber with rhCXCL8 at 10 ng/ml combined with the inhibitor against PI3K (LY294002, 10  $\mu$ M) or MEK1/2 (PD98059, 10  $\mu$ M). DMSO (0.2  $\mu$ l/ml) was added as negative control. After 24 h, the migrated cells were counted. (ii) TE-9 cells were plated on the upper transwell coated with matrigel. rhCXCL8 was added in the transwell combined with LY294002 (10  $\mu$ M) or PD98059 (10  $\mu$ M). DMSO (0.2  $\mu$ l/ml) was added to negative control. After 48 h, the invaded cells were counted. (C) (i) CXCR1- or CXCR2-silenced TE-9 cells were plated on the upper transwell with rhCXCL8 at 10 ng/ml. After 24 h, the migrated cells were counted. (ii) CXCR1- or CXCR2-silenced TE-9 cells were plated on the upper transwell coated with matrigel. rhCXCL8 was added to the transwell at 100 ng/ml. After 48 h, the invaded cells were counted. (D) (i) TE-9 cells were plated on the upper transwell with rhCXCL8 at 10 ng/ml combined with the neutralizing antibody against CXCR1 (0.2  $\mu$ g/ml) or CXCR2 (1.0  $\mu$ g/ml). Mouse IgG (1.0  $\mu$ g/ml) was added to negative control. The concentrations of neutralizing antibodies were based on the manufacturer's instructions. (ii) TE-9 cells were plated on the upper transwell coated with matrigel. rhCXCL8 was added to the upper transwell at 100 ng/ml combined with the neutralizing antibody against CXCR1 (0.2  $\mu$ g/ml) or CXCR2 (1.0  $\mu$ g/ml). Mouse IgG (1.0  $\mu$ g/ml) was added to negative control. After 48 h, the invaded cells were counted. NS, not significant; \* $p$  < 0.05, \*\* $p$  < 0.01, \*\*\* $p$  < 0.001, \*\*\*\* $p$  < 0.0001.




### Supplementary Figure 5: TAM-like PBMo derived macrophages induced the migration and invasion of TE-9 cells.

(A) PBMs ( $1.0 \times 10^5$  cells/well) were seeded on the lower chamber of 24-well plates with M-CSF (25 ng/ml) for 6 days to induce PBMo-derived macrophages, then incubated with 50% TE-9 CM to induce TAM-like PBMo-derived macrophages. After 2 days, the media were replaced with serum-free media. (i) TE-9 cells were plated on the upper transwell at  $5.0 \times 10^5$  cells/well and set on the plate. After 24 h, the migrated cells were counted. (ii) TE-9 cells were plated on the upper transwell coated with matrigel at  $5.0 \times 10^5$  cells/well and set on the plate. After 48 h, the invaded cells were counted. (B) (i) TE-9 cells were plated on the upper transwell with the inhibitor against PI3K (LY294002, 10 nM) or MEK1/2 (PD98059, 10 nM). DMSO (0.2  $\mu$ l/ml) was added to negative control. After 24 h, the migrated cells were counted. (ii) TE-9 cells were plated on the upper matrigel-coated transwell with LY294002 (10 nM) or PD98059 (10 nM). After 48 h, the invaded cells were counted. (C) (i) TE-9 cells were plated on the upper transwell with the neutralizing antibodies against CXCR1 (0.2  $\mu$ g/ml), CXCR2 (1.0  $\mu$ g/ml) or CXCL8 (1.0  $\mu$ g/ml). Mouse IgG (1.0  $\mu$ g/ml) was added to negative control. After 24 h, the migrated cells were counted. The concentrations of neutralizing antibody were based on manufacturer's instructions. (ii) TE-9 cells were plated on the upper matrigel-coated transwell with the neutralizing antibodies against CXCR1 (0.2  $\mu$ g/ml), CXCR2 (1.0  $\mu$ g/ml) or CXCL8 (1.0  $\mu$ g/ml). Mouse IgG (1.0  $\mu$ g/ml) was added to negative control. After 48 h, the invaded cells were counted. The results are mean  $\pm$  SEM. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .

**A****B**

**Supplementary Figure 6: Negative control study of immunofluorescence and immunohistochemistry.** (A) A double immunofluorescence analysis was performed using normal mouse IgG (negative control) (green) in the replacement of mouse anti-CXCL8 antibody and anti-CD11b (red) antibodies on human ESCC tissue. Nuclei were stained with DAPI (blue). Scale bar, 100  $\mu$ m. (B) Immunohistochemical staining using the same human ESCC tissue. Mouse IgG was used as negative control. Scale bar, 100  $\mu$ m.



**Supplementary Figure 7: Expression of CXCR1 and CXCR2 did not associated with disease-free survival and overall survival. (A) (i) (ii) Expression levels of CXCR1 were not related to disease-free survival and overall survival. (B) (i) (ii) Expression levels of CXCR2 were not related to disease-free survival and overall survival.**